<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441217</url>
  </required_header>
  <id_info>
    <org_study_id>MHST2014-05</org_study_id>
    <nct_id>NCT03441217</nct_id>
  </id_info>
  <brief_title>Hyoscine Butylbromide Effect on Duration of Labor</brief_title>
  <official_title>Hyoscine Butylbromide Effect on Duration of Labor in Nulliparous Women: A Randomized, Double Blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Hospital, Panama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sistema Nacional de Investigadores de Panamá</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Thomas Hospital, Panama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the duration of labour (active phase of labour) in nulliparous women with
      gestations between 37 and 41 6/7 weeks when 20 mg of Hyoscine butylbromide was applied
      intravenously and compared with similar patients that received a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 19, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of first stage of labor</measure>
    <time_frame>24 hours</time_frame>
    <description>Time measured from the moment the patient receive the allocated medication/placebo to complete dilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of cervical dilation</measure>
    <time_frame>24 hours</time_frame>
    <description>Speed of cervical dilation (cms/hour) from the moment the patient receive the allocated medication/placebo to complete dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of labor</measure>
    <time_frame>24 hours</time_frame>
    <description>Time measured from the moment the patient receive the allocated medication/placebo to delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal and neonatal complications</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of adverse events (fetal or neonatal)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Labor</condition>
  <arm_group>
    <arm_group_label>Hyoscine Butylbromide 20Mg/1mL Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine Butylbromide 20Mg/1mL Injection</intervention_name>
    <description>Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).</description>
    <arm_group_label>Hyoscine Butylbromide 20Mg/1mL Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low risk gestation between 37 and 41 6/7 weeks.

          -  Cephalic (vertex) presentation.

          -  Spontaneous labor in active phase (4 cms)

        Exclusion Criteria:

          -  Premature rupture of membranes upon arrival at the Labor and Delivery Unit &gt; 4 hours.

          -  Multiple order pregnancy.

          -  Stillbirth.

          -  Any fetal condition that could interfere in the mode of delivery (macrosomia, fetal
             growth restriction, oligohydramnios).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo Reyes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Maternidad del Hospital Santo Tomás</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Navarro Lorena, MD</last_name>
    <phone>5075619</phone>
    <email>navarro_lore28@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geneva González, MD</last_name>
    <phone>5075619</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Thomas Maternity Hospital</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Thomas Hospital, Panama</investigator_affiliation>
    <investigator_full_name>Osvaldo A. Reyes T.</investigator_full_name>
    <investigator_title>Head - Research Department</investigator_title>
  </responsible_party>
  <keyword>Duration of labor</keyword>
  <keyword>Hyoscine butylbromide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

